Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use
than any other foreign compound–metabolizing enzyme in humans. Recently, increasing …

Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and …

The present AST‐IDCOP guidelines update information on BK polyomavirus (BKP yV)
infection, replication, and disease, which impact kidney transplantation (KT), but rarely non …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

Since their introduction circa 35 years ago, calcineurin-inhibitors (CNI) have become the
cornerstone of immunosuppressive therapy in solid organ transplantation. However, CNI's …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Immunosuppression is the major risk factor for BK virus nephropathy (BKVN) after renal
transplantation (RTx). As the individual tacrolimus (Tac) metabolism rate correlates with Tac …